Shingles Vaccine: Heart Attack & Stroke Protection

Synopsis

Shingles is more than a painful rash: research links it to a higher risk of heart attack and stroke in the weeks that follow, which makes early treatment and vaccination worth understanding together.

Stroke and heart attack risk rises sharply in the weeks after shingles.
Antiviral treatment started within 72 hours of the rash reduces complications and the risk of long-term nerve pain.
The shingles vaccine is linked to fewer cardiovascular events, on top of its protection against shingles itself.

Most people think of shingles as just a rash, but research now shows it can also raise the risk of stroke and heart attack in the weeks and months that follow. Shingles is a painful condition caused by the reactivation of the chickenpox virus, which lies dormant in the nervous system after a first infection. Understanding the link means looking beyond the rash: recognising symptoms, seeking early treatment, and considering prevention.

What Is Shingles? How the Herpes Zoster Virus Reactivates

Shingles, also known as herpes zoster, develops when the varicella zoster virus (VZV) that caused your chickenpox reactivates years later. This means shingles can only happen if you have had chickenpox before, as the virus stays silent in your body after the original infection.

It affects around 1 in 3 people during their lifetime, with the risk rising steeply after the age of 50. Anyone who had chickenpox in the past can develop shingles.

The virus can reactivate when the immune system is weakened and can no longer keep it fully suppressed. Common triggers include:

Ageing, which naturally reduces immune function, particularly after age 50
Weakened immunity from conditions such as HIV, cancer, lupus, or rheumatoid arthritis
Medications that suppress the immune system, including long-term steroids, chemotherapy, and certain treatments for inflammatory conditions
Chronic illnesses such as diabetes, heart disease, chronic kidney disease, and depression
Psychological stress, physical fatigue, or acute illness, which can place extra strain on the immune system
A family history of shingles

In many people, especially those over 50, no single trigger can be identified.

Recognising the Early Shingles Symptoms before Complications Set In

Shingles typically develops in three stages:

Before the rash: Burning, itching, or tingling pain along one side of the body or face, often appearing days before any skin changes. Some people also feel tired, have a headache, or run a mild fever.
The rash: A red, blistering rash appears in a stripe or band on one side of the body, most commonly across the chest or abdomen. It does not cross the middle of the body and usually heals within 2 to 4 weeks.
After the rash: Some people, especially those over 60, develop long-lasting nerve pain called postherpetic neuralgia (PHN) in the area where the rash appeared. This can persist for months or even years.

Shingles can also affect the eye area, a form called herpes zoster ophthalmicus, which carries its own serious risks.

How Soon Do You Need Shingles Medication for It to Work?

If you think you have shingles, seeing a doctor promptly is one of the most important steps you can take. Antiviral medicines, such as acyclovir and valacyclovir, are most effective when started within 72 hours of the rash appearing.

Early treatment can:

Reduce the severity and duration of the rash and pain
Speed up healing of the blisters
Lower the risk of developing postherpetic neuralgia (PHN)
Reduce the risk of serious eye complications in shingles affecting the eye area

Starting antiviral treatment within 72 hours may reduce the chance of having persistent pain at 6 months by up to 46%. Even if 72 hours have passed, antiviral treatment may still be recommended, particularly if new blisters are still forming or if the eye is involved.

Do not wait to see if the rash gets better on its own. Shingles can worsen quickly, and the window for the most effective treatment is short. But the rash and nerve pain are not the whole story: the next concern is the link between shingles and cardiovascular events.

Shingles, Heart Attacks, and Stroke: What Recent Studies Reveal

Research involving nearly 8 million patients found that people who have had shingles face a significantly higher risk of stroke and heart attack, particularly in the first few weeks after infection.

The virus can travel from the nerves to the walls of blood vessels, causing inflammation, narrowing, and clotting. This can trigger a stroke or heart attack even in people who have no other known cardiovascular risk factors.

Key findings from published research include:

The risk of stroke is highest in the first week after shingles, at more than twice the usual level during that period.
The risk of heart attack is approximately 35% higher than usual in the 30 days following a shingles episode.
People aged 50 and over face a 36% higher risk of heart attack in the month after shingles.
In shingles affecting the eye area, the risk of stroke can be up to 4 times higher than normal.

The table below summarises higher-risk groups and their reported complications after shingles.

Group	Elevated risk
Adults aged 50 and over	36% higher heart attack risk within 30 days
Shingles affecting the eye area	Up to 4 times higher stroke risk
People with rheumatoid arthritis	27% higher stroke risk compared to those with arthritis but no shingles
Immunocompromised individuals	Combined higher risk from both shingles and cardiovascular disease

The link also runs in the other direction: people who already have cardiovascular disease are more likely to develop shingles in the first place. This makes prevention a particularly relevant topic to discuss with your doctor if you have an existing cardiovascular condition.

Shingles Vaccination: How Prevention Protects Your Heart

If you are unsure whether you have had chickenpox in the past, a simple blood test can check for antibodies to the virus and give you a clear answer.

One of the most effective steps you can take to protect against shingles is vaccination. The recombinant zoster vaccine (RZV) is given as two doses. Studies show that zoster vaccination is linked to:

Protection against shingles for at least 10 years after vaccination
An 18% overall reduction in cardiovascular events
A 22% reduction in stroke risk
Fewer hospitalisations for heart attack and stroke
Cardiovascular protective benefits may last up to 8 years after vaccination

Common side effects of the recombinant zoster vaccine include:

Pain
Redness and swelling at the injection site
Muscle aches
Tiredness
Headache
Chills
Fever
Upset stomach

These are usually mild to moderate, settle within two to three days, and tend to be more noticeable in younger adults.

Vaccination is recommended for adults aged 50 and over, and for younger adults with weakened immune systems. It is worth discussing with your doctor if you have existing heart disease, diabetes, or other long-term health conditions.

If you have recently had shingles and develop any new symptoms such as chest pain, sudden weakness, numbness, or difficulty speaking, seek medical attention promptly.

The Bottom Line on Shingles Vaccination and Long-Term Wellness

If you develop a shingles rash, seek treatment early: the window for antiviral medicines is short. For longer-term prevention, talk to your doctor about whether the shingles vaccine is right for you. Shingles is more than a skin condition; it carries a real, measurable risk of serious cardiovascular events, especially in older adults. Vaccination offers meaningful protection against the pain and rash of shingles, with potential protection against heart attack and stroke as well.

Dr Shiba Poon

General Practice, Family Medicine

LMCHK
MBBS (Lond)
DRCOG
DCH (RCPCH)
PGDipClinDerm (Lond)
MRCGP
Honorary Clinical Assistant Professor In Family Medicine (HKU)

View Profile

Health Articles by Dr Shiba Poon

References

Centers for Disease Control and Prevention (CDC) (2024) Shingles facts and stats. Available at: https://www.cdc.gov/shingles/data-research/index.html (Accessed: 31 October 2026).
Yamaoka-Tojo, M. and Tojo, T. (2024) 'Herpes zoster and cardiovascular disease: exploring associations and preventive measures through vaccination', Vaccines, 12(3), p. 252. doi: 10.3390/vaccines12030252. Available at: https://www.mdpi.com/2076-393X/12/3/252 (Accessed: 31 October 2026).
Marra, F., Parhar, K., Huang, B. and Vadlamudi, N. (2020) 'Risk factors for herpes zoster infection: a meta-analysis', Open Forum Infectious Diseases, 7(1), p. ofaa005. doi: 10.1093/ofid/ofaa005. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6984676 (Accessed: 31 October 2026).
Lasserre, A., Blaizeau, F., Gorwood, P., Bloch, K., Chauvin, P., Liard, F., Blanchon, T., & Hanslik, T. (2012) 'Herpes zoster: family history and psychological stress — case-control study', Journal of Clinical Virology, 55(2), pp. 153–157. doi: 10.1016/j.jcv.2012.06.020. Available at: https://pubmed.ncbi.nlm.nih.gov/22824229 (Accessed: 31 October 2026).
Chen, L.K., Arai, H., Chen, L.Y., Chou, M.Y., Djauzi, S., Dong, B., Kojima, T., Kwon, K.T., Leong, H.N., Leung, E.M., Liang, C.K., Liu, X., Mathai, D., Pan, J.Y., Peng, L.N., Poblete, E.R., Poi, P.J., Reid, S., Tantawichien, T. and Won, C.W. (2017) 'Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific', BMC Infectious Diseases, 17, p. 213. doi: 10.1186/s12879-017-2198-y. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5353949 (Accessed: 31 October 2026).
Freund, P.R. and Chen, S.H. (2018) 'Herpes zoster ophthalmicus', CMAJ, 190(21), p. E656. doi: 10.1503/cmaj.180063. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5973887 (Accessed: 31 October 2026).
Jackson, J.L., Gibbons, R., Meyer, G. and Inouye, L. (1997) 'The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis', Archives of Internal Medicine, 157(8), pp. 909–912. doi: 10.1001/archinte.1997.00440290095010. Available at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/623237 (Accessed: 31 October 2026).
Minor, M., Gurnani, B. and Payne, E. (2026) 'Herpes zoster ophthalmicus', in StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Updated 14 September 2025. Available at: https://www.ncbi.nlm.nih.gov/sites/books/NBK557779 (Accessed: 31 October 2026).
Parameswaran, G.I., et al. (2023) 'Increased myocardial infarction risk following herpes zoster infection', Open Forum Infectious Diseases, 10(4), p. ofad137. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10077824/ (Accessed: 6 November 2026).
Liao, T.L., Lin, C.H., Chen, H.H., Chen, Y.M., Lin, C.C. and Chen, D.Y. (2017) 'Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients', Journal of the American Heart Association, 6(7), p. e006304. doi: 10.1161/JAHA.117.006304. Available at: https://www.ahajournals.org/doi/pdf/10.1161/JAHA.117.006304 (Accessed: 6 November 2026).
Rayens, E., et al (2025). Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clinical infectious diseases, 81(5), e441–e445. Available at: https://doi.org/10.1093/cid/ciaf440 (Accessed: 6 November 2026).
Erskine, N., Tran, H., Levin, L., Ulbricht, C., Fingeroth, J., Kiefe, C., Goldberg, R.J. and Singh, S. (2017) 'A systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular events', PLOS ONE, 12(7), p. e0181565. doi: 10.1371/journal.pone.0181565. Available at: https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0181565 (Accessed: 31 October 2026).
Minassian, C., Thomas, S.L., Smeeth, L., Douglas, I., Brauer, R. and Langan, S.M. (2015) 'Acute cardiovascular events after herpes zoster: a self-controlled case series analysis in vaccinated and unvaccinated older residents of the United States', PLOS Medicine, 12(12), p. e1001919. doi: 10.1371/journal.pmed.1001919. Available at: https://journals.plos.org/plosmedicine/article?id=10.1371%2Fjournal.pmed.1001919 (Accessed: 31 October 2026).
Kim, MC., Yun, SC., Lee, HB., Lee, P.H., Lee, SW., Choi, SH., Kim, Y.S., Woo, J.H., Kim, S-H. and Kwon, S.U. (2017) 'Herpes zoster increases the risk of stroke and myocardial infarction', Journal of the American College of Cardiology, 70(2), pp. 295–296. doi: 10.1016/j.jacc.2017.05.015. Available at: https://www.jacc.org/doi/10.1016/j.jacc.2017.05.015 (Accessed: 31 October 2026).
Langan, S.M., Minassian, C., Smeeth, L. and Thomas, S.L. (2014) 'Risk of stroke following herpes zoster: a self-controlled case-series study', Clinical Infectious Diseases, 58(11), pp. 1497–1503. doi: 10.1093/cid/ciu098. Available at: https://academic.oup.com/cid/article/58/11/1497/2895264 (Accessed: 31 October 2026).
Centers for Disease Control and Prevention (CDC) (2024) Laboratory testing for varicella-zoster virus (VZV). Available at: https://www.cdc.gov/chickenpox/php/laboratories (Accessed: 31 October 2026).
Strezova, A., Diez-Domingo, J., Al Shawafi, K., Tinoco, J.C., Shi, M., Pirrotta, P., Mwakingwe-Omari, A. and Zoster-049 Study Group (2022) 'Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination', Open Forum Infectious Diseases, 9(10), p. ofac485. doi: 10.1093/ofid/ofac485. Available at: https://pubmed.ncbi.nlm.nih.gov/36299530 (Accessed: 31 October 2026).
Williams, C, et al. (2025) 'Herpes zoster vaccine effectiveness against cardiovascular events: a systematic literature review and meta-analysis', European Heart Journal, 46(Supplement 1), p. ehaf784.3633. doi: 10.1093/eurheartj/ehaf784.3633. Available at: https://academic.oup.com/eurheartj/article/46/Supplement_1/ehaf784.3633/8312335 (Accessed: 31 October 2026).
Jia, Y-H., Dong, Y-B., Jiang, H-Y., Shi, M-J., Zhao, Q., Zhu, R-X. and He, L. (2023) 'Effects of herpes zoster vaccination and antiviral treatment on the risk of stroke: a systematic review and meta-analysis', Frontiers in Neurology, 14, p. 1176920. doi: 10.3389/fneur.2023.1176920. Available at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1176920 (Accessed: 31 October 2026).
Helm, M.F., Khoury, P.A., Warne, M., Maczuga, S., Chinchilli, V.M., Butt, M., Morawo, A. and Foulke, G.T. (2024) 'Zoster vaccine lowers stroke and myocardial infarction risk in chronic disease', American Journal of Preventive Medicine, 67(5), pp. 676–683. doi: 10.1016/j.amepre.2024.06.018. Available at: https://www.ajpmonline.org/article/S0749-3797(24)00215-0/abstract (Accessed: 31 October 2026).
Lee, S., Lee, K., Oh, J., Kim, H.J., Son, Y., Kim, S., Park, J., Kang, J., Pizzol, D., Lee, J., Woo, H.G., Lee, H. and Yon, D.K. (2025) 'Live zoster vaccination and cardiovascular outcomes: a nationwide, South Korean study', European Heart Journal, 46(30), pp. 2991–3002. doi: 10.1093/eurheartj/ehaf230. Available at: https://academic.oup.com/eurheartj/article/46/30/2991/8124786 (Accessed: 31 October 2026).
Centers for Disease Control and Prevention (CDC) (2024) Shingles (Herpes Zoster) Vaccine Safety. Available at: https://www.cdc.gov/vaccine-safety/vaccines/shingles-herpes.html (Accessed: 6 November 2026).